PDB Remediates Archive, Creates New Set of Corrected Files
The worldwide Protein Data Bank has remediated its files and created a new set, the Research Collaboratory for Structural Bioinformatics and other member organizations of the wwPDB said in a notice this week.
“The evolution of experimental methods, functional knowledge of proteins, and methods used to process PDB data has introduced inconsistencies into the archive,” according to the wwPDB website. Therefore, the wwPDB members “remediated” the data in order to create a more “uniform” archive.
The archive has been reviewed in order to improve the chemical description of non-polymer and monomer chemical components; standardize atom nomenclature; update sequence database references and taxonomies; resolve any remaining differences between chemical and macromolecular sequences; improve the representation of viruses; and verify primary citation assignments.
In addition, PDB’s atom nomenclature for amino acids and nucleotides now conforms with International Union of Pure and Applied Chemistry standards.
Detailed information about the remediation project can be found here.
Atrium Research Pegs Potential E-Lab Notebook Market at $1.7B
According to a new market research report from Atrium Research of Wilton, Conn., the potential market for electronic laboratory notebooks is worth $1.7 billion, and the sector is growing at an annual rate of 30 percent.
The report, “Electronic Laboratory Notebooks: A Foundation for Scientific Knowledge Management,” examines the proliferation of ELNs and their segue from specific uses in synthetic chemistry, for example, to becoming more of “a mainstream laboratory informatics technology.”
Benefits of ELNs include enhanced research capability and knowledge sharing, according to Atrium.
Atrium said that there are currently more than 30 ELN suppliers, and that these companies sold around $43 million worth of products and services in 2006.
Eppendorf to Market Polyclone’s Real-Time PCR Primer- and Probe-Design Software
Polyclone Bioservices said this week that Eppendorf India will globally market its Eprime software for designing primers for both qualitative and quantitative PCR studies.
Polyclone, based in Bangalore, India, said that Eprime enables researchers to design primers and probes for quantitative studies as well as oligos for gene-expression studies.
The company said that Eppendorf India will bundle the software with every real-time PCR instrument that it sells.
Financial terms of the agreement were not disclosed.
Entelos and Jubilant to Co-Develop Therapeutics, Offer Joint Services
Biosimulation firm Entelos said this week that it will join forces with Jubilant BioSys to discover, in-license, and further develop a portfolio of compounds, as well as develop and offer a range of services to expand their respective businesses in pharmaceuticals and biotech.
The combined offerings include predictive biosimulation, modeling, and preclinical and clinical testing, as well as drug formulation, synthesis, manufacturing, and supply.
Galapagos Closes Inpharmatica Acquisition for $16.2M
Galapagos this week said it has issued a final tranche of 113,378 shares to close its acquisition of Inpharmatica. The final purchase price was €12 million ($16.2 million).
Galapagos announced in December that it was acquiring the UK-based company in a share exchange over three tranches worth as much as €19.1 million [BioInform 12-08-06].
Last month, Galapagos cut around €7 million from the value of the acquisition because Inpharmatica had failed to meet certain milestones that were a condition of the purchase [BioInform 04-13-07].
Galapagos plans to fold Inpharmatica into its drug-discovery services business, BioFocus DPI.
Under the deal, Inpharmatica contributed C Preference shares to Galapagos in exchange for a total of 2,165,532 newly issued Galapagos shares.
A first tranche of 623,582 Galapagos shares was issued in December, and another trance of 613,270 shares was issued in April. The final tranche was issued this week, bringing the total exchange to around €12 million.